Back to top

Tale of the Tape

Zacks Equity Research

Keryx Biopharmaceuticals (KERX) Enters Overbought Territory
September 18, 2013


Save at Trade
Keryx Biopharmaceuticals (KERX - Analyst Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because KERX is now in overbought territory with an RSI value of 71.37. Furthermore, estimates for the Keryx Biopharmaceuticals have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.